Advanced Real-Time Chart | Trending Stocks Technical Indicators
*Stock Markets - Austria, Belgium, Denmark, Finland, France, Germany, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK, US
Wallbridge Intersects High-Grade Gold Veins up to 800 Metres Northwest of Fenelon's Known Footprint
TORONTO, Jan. 27, 2020 /CNW/ - Wallbridge Mining Company Limited (TSX: WM, FWB: WC7) ("Wallbridge" or the "Company") is pleased to announce assay results from the previously reported VG intersection in FA-19-089 and other mineralized intervals in grassroots drill holes completed in 2019 on its 100%-owned Fenelon Gold Property ("Fenelon" or the "Property"). FA-19-089, the first hole to test a target 800 m along strike to the northwest of the known footprint of the Area 51 gold system, intersected 83.18 g/t over 0.51 metres, highlighting the excellent potential for Area-51-style gold mineralization along the approximately four kilometre strike length of the Jeremie Pluton.
Instructure Comments on ISS Report Regarding Proposed Thoma Bravo Acquisition
SALT LAKE CITY, Jan. 27, 2020 /PRNewswire/ -- Instructure (NYSE: INST) today issued the following statement in response to the recommendation issued by Institutional Shareholder Services Inc. ("ISS") regarding the Company's previously announced definitive merger agreement to be acquired by Thoma Bravo, LLC for $47.60 per share in cash.
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 27, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Trijardy(TM) XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy XR provides three type 2 diabetes medicines in one pill, including Jardiance(®) (empagliflozin), Tradjenta(®) (linagliptin) and metformin hydrochloride extended release. Trijardy XR is marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY).
Grupo LALA schedules Fourth Quarter 2019 Earnings Conference Call for Tuesday, February 25, 2020
MEXICO CITY, Jan. 27, 2020 /PRNewswire/ -- Grupo LALA, S.A.B. de C.V., a Mexican Company focused on healthy and nutritious foods ("LALA") (BMV "LALAB"), will host a conference call to discuss Fourth Quarter 2019 Results.